Effect of dehydroepiandrosterone replacement on lipoprotein profile in hypoadrenal women

Manivannan Srinivasan, Brian A. Irving, Ketan Dhatariya, Katherine A. Klaus, Stacy J. Hartman, Joseph P. McConnell, K Sreekumaran Nair

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Context: Levels of dehydroepiandrosterone (DHEA) and its sulfate form (DHEAS) are inversely associated with cardiovascular mortality in men but not women. Very little evidence is available on the impact of DHEA administration on lipoprotein profile in women. DHEAS levels are very low/ undetectable in hypoadrenal women. Objective: The objective of the study was to determine the impact of DHEA replacement on lipoprotein profile in hypoadrenal women. Design and Setting: A double-blind, randomized, placebo-controlled, cross-over design study was conducted at the Mayo Clinic. Participants: Thirty-three hypoadrenal Caucasian women (mean ± sd; age 50.3 ± 15.2 yr, body mass index 26.6 ± 4.4 kg/m 2) took part in the study. Intervention: Study participants were assigned to receive either a placebo or 50 mg/d of DHEA for 3 months each. Lipid levels and lipoprotein profile were analyzed using the Lipo Science Lipoprotein nuclear magnetic resonance system. Main Outcome Measures: Changes in various lipoprotein sizes and levels were measured. Results: The DHEA period had higher plasma DHEAS levels than during placebo (<0.3 ± 0.0 vs. 3.5 ± 1.3 nmol/liter, P< 0.001). DHEA replacement significantly reduced total cholesterol (20.0 vs. -22, P = 0.02) and high-density lipoprotein (HDL) levels (2.0 vs. -6.0, P = 0.006) and tends to reduce triglyceride and total low-density lipoprotein levels. Although, DHEA replacement had no effect on low-density lipoprotein particle size, it significantly reduced larger HDL particles and to modest extent small HDL particles.Conclusions: Our study findings showed that oral DHEA administration in hypoadrenal women results in an unfavorable lipoprotein profile. The results warrant long-term studies to determine the impact of DHEA replacement on cardiovascular risk.

Original languageEnglish (US)
Pages (from-to)761-764
Number of pages4
JournalJournal of Clinical Endocrinology and Metabolism
Volume94
Issue number3
DOIs
StatePublished - Mar 2009

Fingerprint

Dehydroepiandrosterone
Lipoproteins
HDL Lipoproteins
Placebos
LDL Lipoproteins
Cross-Over Studies
Dehydroepiandrosterone Sulfate
Particle Size
Oral Administration
Triglycerides
Body Mass Index
Magnetic Resonance Spectroscopy
Particle size
Cholesterol
Nuclear magnetic resonance
Outcome Assessment (Health Care)
Lipids
Plasmas
Mortality

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Endocrinology
  • Biochemistry, medical
  • Endocrinology, Diabetes and Metabolism

Cite this

Effect of dehydroepiandrosterone replacement on lipoprotein profile in hypoadrenal women. / Srinivasan, Manivannan; Irving, Brian A.; Dhatariya, Ketan; Klaus, Katherine A.; Hartman, Stacy J.; McConnell, Joseph P.; Nair, K Sreekumaran.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 94, No. 3, 03.2009, p. 761-764.

Research output: Contribution to journalArticle

Srinivasan, Manivannan ; Irving, Brian A. ; Dhatariya, Ketan ; Klaus, Katherine A. ; Hartman, Stacy J. ; McConnell, Joseph P. ; Nair, K Sreekumaran. / Effect of dehydroepiandrosterone replacement on lipoprotein profile in hypoadrenal women. In: Journal of Clinical Endocrinology and Metabolism. 2009 ; Vol. 94, No. 3. pp. 761-764.
@article{c47e47bd856b4d29b9b068aed6b6e372,
title = "Effect of dehydroepiandrosterone replacement on lipoprotein profile in hypoadrenal women",
abstract = "Context: Levels of dehydroepiandrosterone (DHEA) and its sulfate form (DHEAS) are inversely associated with cardiovascular mortality in men but not women. Very little evidence is available on the impact of DHEA administration on lipoprotein profile in women. DHEAS levels are very low/ undetectable in hypoadrenal women. Objective: The objective of the study was to determine the impact of DHEA replacement on lipoprotein profile in hypoadrenal women. Design and Setting: A double-blind, randomized, placebo-controlled, cross-over design study was conducted at the Mayo Clinic. Participants: Thirty-three hypoadrenal Caucasian women (mean ± sd; age 50.3 ± 15.2 yr, body mass index 26.6 ± 4.4 kg/m 2) took part in the study. Intervention: Study participants were assigned to receive either a placebo or 50 mg/d of DHEA for 3 months each. Lipid levels and lipoprotein profile were analyzed using the Lipo Science Lipoprotein nuclear magnetic resonance system. Main Outcome Measures: Changes in various lipoprotein sizes and levels were measured. Results: The DHEA period had higher plasma DHEAS levels than during placebo (<0.3 ± 0.0 vs. 3.5 ± 1.3 nmol/liter, P< 0.001). DHEA replacement significantly reduced total cholesterol (20.0 vs. -22, P = 0.02) and high-density lipoprotein (HDL) levels (2.0 vs. -6.0, P = 0.006) and tends to reduce triglyceride and total low-density lipoprotein levels. Although, DHEA replacement had no effect on low-density lipoprotein particle size, it significantly reduced larger HDL particles and to modest extent small HDL particles.Conclusions: Our study findings showed that oral DHEA administration in hypoadrenal women results in an unfavorable lipoprotein profile. The results warrant long-term studies to determine the impact of DHEA replacement on cardiovascular risk.",
author = "Manivannan Srinivasan and Irving, {Brian A.} and Ketan Dhatariya and Klaus, {Katherine A.} and Hartman, {Stacy J.} and McConnell, {Joseph P.} and Nair, {K Sreekumaran}",
year = "2009",
month = "3",
doi = "10.1210/jc.2008-1774",
language = "English (US)",
volume = "94",
pages = "761--764",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "3",

}

TY - JOUR

T1 - Effect of dehydroepiandrosterone replacement on lipoprotein profile in hypoadrenal women

AU - Srinivasan, Manivannan

AU - Irving, Brian A.

AU - Dhatariya, Ketan

AU - Klaus, Katherine A.

AU - Hartman, Stacy J.

AU - McConnell, Joseph P.

AU - Nair, K Sreekumaran

PY - 2009/3

Y1 - 2009/3

N2 - Context: Levels of dehydroepiandrosterone (DHEA) and its sulfate form (DHEAS) are inversely associated with cardiovascular mortality in men but not women. Very little evidence is available on the impact of DHEA administration on lipoprotein profile in women. DHEAS levels are very low/ undetectable in hypoadrenal women. Objective: The objective of the study was to determine the impact of DHEA replacement on lipoprotein profile in hypoadrenal women. Design and Setting: A double-blind, randomized, placebo-controlled, cross-over design study was conducted at the Mayo Clinic. Participants: Thirty-three hypoadrenal Caucasian women (mean ± sd; age 50.3 ± 15.2 yr, body mass index 26.6 ± 4.4 kg/m 2) took part in the study. Intervention: Study participants were assigned to receive either a placebo or 50 mg/d of DHEA for 3 months each. Lipid levels and lipoprotein profile were analyzed using the Lipo Science Lipoprotein nuclear magnetic resonance system. Main Outcome Measures: Changes in various lipoprotein sizes and levels were measured. Results: The DHEA period had higher plasma DHEAS levels than during placebo (<0.3 ± 0.0 vs. 3.5 ± 1.3 nmol/liter, P< 0.001). DHEA replacement significantly reduced total cholesterol (20.0 vs. -22, P = 0.02) and high-density lipoprotein (HDL) levels (2.0 vs. -6.0, P = 0.006) and tends to reduce triglyceride and total low-density lipoprotein levels. Although, DHEA replacement had no effect on low-density lipoprotein particle size, it significantly reduced larger HDL particles and to modest extent small HDL particles.Conclusions: Our study findings showed that oral DHEA administration in hypoadrenal women results in an unfavorable lipoprotein profile. The results warrant long-term studies to determine the impact of DHEA replacement on cardiovascular risk.

AB - Context: Levels of dehydroepiandrosterone (DHEA) and its sulfate form (DHEAS) are inversely associated with cardiovascular mortality in men but not women. Very little evidence is available on the impact of DHEA administration on lipoprotein profile in women. DHEAS levels are very low/ undetectable in hypoadrenal women. Objective: The objective of the study was to determine the impact of DHEA replacement on lipoprotein profile in hypoadrenal women. Design and Setting: A double-blind, randomized, placebo-controlled, cross-over design study was conducted at the Mayo Clinic. Participants: Thirty-three hypoadrenal Caucasian women (mean ± sd; age 50.3 ± 15.2 yr, body mass index 26.6 ± 4.4 kg/m 2) took part in the study. Intervention: Study participants were assigned to receive either a placebo or 50 mg/d of DHEA for 3 months each. Lipid levels and lipoprotein profile were analyzed using the Lipo Science Lipoprotein nuclear magnetic resonance system. Main Outcome Measures: Changes in various lipoprotein sizes and levels were measured. Results: The DHEA period had higher plasma DHEAS levels than during placebo (<0.3 ± 0.0 vs. 3.5 ± 1.3 nmol/liter, P< 0.001). DHEA replacement significantly reduced total cholesterol (20.0 vs. -22, P = 0.02) and high-density lipoprotein (HDL) levels (2.0 vs. -6.0, P = 0.006) and tends to reduce triglyceride and total low-density lipoprotein levels. Although, DHEA replacement had no effect on low-density lipoprotein particle size, it significantly reduced larger HDL particles and to modest extent small HDL particles.Conclusions: Our study findings showed that oral DHEA administration in hypoadrenal women results in an unfavorable lipoprotein profile. The results warrant long-term studies to determine the impact of DHEA replacement on cardiovascular risk.

UR - http://www.scopus.com/inward/record.url?scp=62349110320&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=62349110320&partnerID=8YFLogxK

U2 - 10.1210/jc.2008-1774

DO - 10.1210/jc.2008-1774

M3 - Article

C2 - 19066301

AN - SCOPUS:62349110320

VL - 94

SP - 761

EP - 764

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 3

ER -